- Mr. Josh Bartch, the CEO, Chairman, and Co-Founder of Mydecine, attributed the company’s success to its phased approach to product research and development
- He noted significant strides in smoking cessation and PTSD research over the 2021 calendar year, which will be integral to operations in the new year
- Mr. Bartch was also proud of the current efficacy data around psilocybin to treat nicotine dependance which is significantly better than what is available in the market
- Going into 2022, Mydecine will embark on more clinical studies on smoking cessation and PTSD, focus more on novel compound production and growing its Mindleap digital health platform
Josh Bartch, the Co-Founder, Chairman, and Chief Executive Officer (“CEO”) of Mydecine Innovations Group (NEO: MYCO) (OTC: MYCOF) (FSE: ONFA), recently appeared on The Bell2BellPodcast, a platform meant to highlight key organizations, leaders and entrepreneurs who are leaving a mark in their respective industries.
Mr. Bartch briefly shared his background, leading up to co-founding Mydecine, along with the goals for the company for the new year. Of note was Mydecine’s phased approach, which Bartch noted is integral to the company’s operations, along with its future.
“Mydecine Innovations Group…is really focused on first- and second-generation novel therapeutics derived from different psychedelic molecules. We’re using those as a blueprint or starting point and then making several improvements for what we call second-generation psychedelic molecules for the treatment of a number of indications,” Bartch noted (https://ibn.fm/kLsnW).
So far, Mydecine addresses two lead indications- smoking cessation and PTSD. In 2021, the company partnered with Johns Hopkins University (“JHU”) for further research on smoking cessation and has so far made some significant strides in PTSD treatment. In addition, its phased approach, which entails understanding the imperfections of initial formulations and then modifying them to make them more effective, has already set the company apart from its peers. As a result, the first generation of products is already proving significantly better than what is currently available in the market.
“For smoking cessation, for instance, you’re looking at no good solutions currently available,” noted Mr. Bartch.
“You have Chantix, which was recently recalled for a cancer-causing carcinogen…Even before, when it was still available on the shelf, this is a blockbuster drug doing $1.2 billion per year with efficacy data in the single digits at 12 months,” he added.
With what Mydecine is offering, Bartch noted, early-stage trials have proven to be way better than what was available in the market. Efficacy data has shown upwards of 80% in six months and 67% at 12 months, all attributed to its phased approach.
“Through our phased approach, we take that first generation, look at imperfections and make improvements- things in the nature of half-life, controllability delivery time, onset time, anxiety associated with different molecules, etc.,” Bartch reckoned.
Going into 2022, Mr. Bartch was keen to note that Mydecine will start two clinical trials- a smoking cessation study and a PTSD Phase 2a study. He also noted the company’s commitment to focusing more on novel compound production and getting them to clinics around the country, which will also be accompanied by publishing pre-clinical results following the studies carried out so far. 2022 will also be the year when Mydecine commercializes its Mindleap digital health platform, as it focuses on growing the number of its users and further improving its offering.
To listen to the whole podcast, please visit https://ibn.fm/JQwe2
For more information, visit the company’s website at www.Mydecine.com.
NOTE TO INVESTORS: The latest news and updates relating to MYCOF are available in the company’s newsroom at https://ibn.fm/MYCOF
About PsychedelicNewsWire
PsychedelicNewsWire (PNW) is a specialized content distribution company that (1) aggregates and distributes news and information on the latest developments in all aspects and advances of psychedelics and their use, (2) creates PsychedelicNewsBreaks designed to quickly update investors on important industry news, (3) leverages a team of expert editors to enhance press releases for maximum impact, (4) assists companies with the management and optimization of social media across a range of platforms, and (5) delivers unparalleled corporate communication solutions. PNW stays abreast of the latest information and has established a reputation as the go to source for coverage of psychedelics, therapeutics and emerging market opportunities. Our team of seasoned journalists has a proven track record of helping both public and private companies gain traction with a wide audience of investors, consumers, media outlets and the general public by leveraging our expansive dissemination network of more than 5,000 key syndication outlets. PNW is committed to delivering improved visibility and brand recognition to companies operating in the emerging markets of psychedelics.
To receive instant SMS alerts, text “Groovy” to 888-902-4192 (U.S. Mobile Phones Only)
For more information please visit https://www.psychedelicnewswire.com
Please see full terms of use and disclaimers on the PsychedelicNewsWire website applicable to all content provided by PNW, wherever published or re-published: https://www.psychedelicnewswire.com/Disclaimer
Do you have questions or are you interested in working with PNW? Ask our Editor
PsychedelicNewsWire (PNW)
San Francisco, California
www.psychedelicnewswire.com
415.949.5050 Office
Editor@PsychedelicWire.com
PsychedelicNewsWire is part of the InvestorBrandNetwork.
